Valuation: CombiGene AB

Market Cap 4.55Cr 47.24L 41.32L 38.12L 35.2L 66.8L 45Cr 67.92L 1.79Cr 22Cr 1.77Cr 1.74Cr 76Cr P/E 2024
-1.05x
P/E 2025 -3.62x
Enterprise Value 3.97Cr 41.18L 36.02L 33.23L 30.69L 58.23L 39Cr 59.21L 1.56Cr 19Cr 1.55Cr 1.51Cr 67Cr EV / Sales 2024
-13.3x
EV / Sales 2025 128x
Free-Float
44.24%
Yield 2024
8.4%
Yield 2025 88.5%
1 week+2.68%
Current month+2.22%
1 month+1.32%
3 months+5.99%
6 months+1.32%
Current year+1.77%
1 week 2.21
Extreme 2.21
2.38
1 month 2.18
Extreme 2.18
2.4
Current year 1.75
Extreme 1.75
2.6
1 year 1.75
Extreme 1.75
2.87
3 years 1.27
Extreme 1.27
7.4
5 years 1.27
Extreme 1.27
20.05
10 years 1.27
Extreme 1.27
147
Manager TitleAgeSince
Chief Executive Officer 48 31/07/2025
Director TitleAgeSince
Director/Board Member 54 10/12/2024
Chairman - 01/01/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.68%-5.35%-67.14% 47.24L
+1.84%-0.66%+59.82%+94.48% 5.49TCr
-4.14%-8.06%+58.96%+125.71% 5.46TCr
-2.24%+3.59%+17.75%+469.23% 2.51TCr
-1.60%-6.21%-18.96%-16.06% 2.31TCr
-1.32%-0.95%+39.96%-8.01% 1.99TCr
-3.19%0.00%+35.60%-27.49% 1.75TCr
-6.84%+2.18%+195.12%+364.56% 1.65TCr
-4.24%-5.56%+44.22%+621.75% 1.57TCr
-1.05%+1.16%+25.95%+191.69% 1.42TCr
Average -2.29%+0.02%+45.31%+174.87% 2.42TCr
Weighted average by Cap. -2.06%-1.45%+50.56%+171.07%

Financials

2024 2025
Net sales 19.99L 2L 2L 2L 2L 3L 1.98Cr 3L 8L 97.44L 8L 8L 3.35Cr 3L 31.54T 27.58T 25.44T 23.5T 44.59T 30.08L 45.34T 1L 14.82L 1L 1L 50.94L
Net income -4.49Cr -46.55L -40.72L -37.56L -34.69L -65.82L -44Cr -66.93L -1.76Cr -22Cr -1.75Cr -1.71Cr -75Cr -1.24Cr -12.82L -11.21L -10.34L -10L -18.13L -12Cr -18.43L -48.53L -6.02Cr -48.14L -47.09L -21Cr
Net Debt -7.37Cr -76.5L -66.92L -61.72L -57.01L -1.08Cr -73Cr -1.1Cr -2.9Cr -36Cr -2.87Cr -2.81Cr -123.57Cr -58.42L -6L -5L -5L -5L -9L -5.78Cr -9L -22.94L -2.85Cr -22.75L -22.26L -9.79Cr
Logo CombiGene AB
Larkberget AB, formerly Combigene AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.
Employees
5
Date Price Change Volume
10/26/10 SEK 2.300 0.00% 2,663
09/26/09 SEK 2.300 +0.44% 3,142
08/26/08 SEK 2.290 +1.78% 14,400
07/26/07 SEK 2.250 +0.90% 5,976
06/26/06 SEK 2.230 -0.45% 2,951
  1. Stock Market
  2. Stocks
  3. LARK Stock